NYSE · DGXHealthcareMedical Labs

Quest Diagnostics financials

$237.62+0.55%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
FY17
Dec 31
FY16
Dec 31
Revenue$11.04B$9.87B$9.25B$9.88B$10.79B$9.44B$7.73B$7.53B$7.40B$7.21B
Gross profit$3.67B$3.24B$3.05B$3.43B$4.21B$3.63B$2.69B$2.60B$2.68B$2.60B
Gross margin33.2%32.9%33.0%34.7%39.0%38.5%34.8%34.6%36.2%36.0%
Operating income$1.54B$1.35B$1.30B$1.43B$2.38B$1.97B$1.23B$1.10B$1.17B$1.16B
Net income$988.0M$866.0M$850.0M$942.0M$1.99B$1.43B$835.0M$733.0M$769.0M$642.0M
Net margin9.0%8.8%9.2%9.5%18.4%15.1%10.8%9.7%10.4%8.9%
Diluted EPS$8.75$7.69$7.49$7.97$15.55$10.47$6.14$5.28$5.50$4.51
EBITDA$2.11B$1.84B$1.74B$1.86B$2.79B$2.33B$1.56B$1.41B$1.44B$1.41B
Operating cash flow$1.89B$1.33B$1.27B$1.72B$2.23B$2.00B$1.24B$1.20B$1.18B$1.12B
Free cash flow$1.36B$909.0M$864.0M$1.31B$1.83B$1.59B$843.0M$817.0M$923.0M$823.0M
Diluted shares113.0M112.6M113.5M118.0M128.0M136.0M136.0M139.0M140.0M142.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$420.0M$549.0M$686.0M$315.0M$872.0M$1.16B
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$5.67B$6.22B$4.71B$3.98B$4.01B$4.01B
Total assets$16.23B$16.15B$14.02B$12.84B$13.61B$14.03B
Total liabilities$8.94B$9.26B$7.60B$6.83B$7.05B$7.13B
Shareholders' equity$7.21B$6.81B$6.34B$5.93B$6.48B$6.81B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology